A. A man in his early 30's with shortness of breath and edema. B. A man in his late 50's with exercise intolerance and fatigue. C. A woman in her early 30's with shortness of breath and edema. D. A woman in her late 50's with exercise intolerance and fatigue. E. Unsure

A. It is easily discernable from other common causes of shortness of breath. B. It can often take years from symptom onset to final diagnosis. C. Diagnosis delays do not impact patient outcomes in a major way. D. Diagnosis is often done by primary care providers. E. Unsure

A. Change in Functional Classification B. World Health Organization Group C. Mean pulmonary arterial pressure D. 6-minute walk distance E. Unsure

A. Slight limitation in physical activity B. Inability to carry out physical activity C. Marked limitation on physical activity D. No limitations in physical activity E. Unsure

A. Epoprostenol B. Treprostinil C. Iloprost D. Selexipag E. Unsure

A. Bosentan B. Riociguat C. Sildenafil D. Selexipag E. Unsure

A. Soluble guanylate cyclase stimulator B. Endothelin receptor antagonists C. Phosphodiesterase 5 inhibitors D. Prostacyclin receptor agonist E. Unsure

A. Riociguat and bosentan B. Riociguat and treprostinil C. Riociguat and selexipag D. Riociguat and sildenafil E. Unsure

A. Treprostinil and selexipag B. Sildenafil and bosentan C. Epoprostenol monotherapy D. Tadalafil and ambrisentan E. Unsure

A. Motivational interviewing is an effective one-time use tool to implement change B. Patients with adverse events to prior medications will be more likely to adhere to future therapy. C. Patients may be relieved when being diagnosed with PAH because they understand what is causing their symptoms. D. The typical time to diagnosis of PAH allows patients to implement lifestyle changes shortly after symptom onset. E. Unsure